Therapeutic method

Included anti-inflammatory, cough and asthma relief; the main drugs were ambroxol hydrochloride oral liquid (Harbin Renhuang Pharmaceutical Co., Ltd.; SFDA Approval no. H20067008) 10 ml/time, twice a day, tiobutramine bromide powder inhaler (Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd.; SFDA Approval no. H20060454), one each time, once a day, with nutritional support and lung rehabilitation training.

On the basis of the control group, tetrandrine combined with N-acetylcysteine was given. Tetrandrine (Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical; SFDA Approval no. 2236H1330) 60 mg-100 mg/time, 3 times a day, taken for 6 days and then stopped for 1 day, with a course of treatment of 3 months. Acetylcysteine effervescent tablets (Zambon S.p.A.; SFDA Approval no. H20140449) 1 tablet/time, 1–2 times/day. The treatment lasted 8 months in both groups.

The curative effect of the two groups was analyzed by X-ray, and the incidence of adverse reactions was compared between the two groups. The changes of pulmonary function indexes and the distance of 6-min walking test were analyzed in the groups. The changes of IL-6 and TNF-α in the peripheral blood of the two groups were measured before and after treatment, and the relationship between IL-6, TNF-α and the therapeutic effect was analyzed.

Efficacy assessment methods: TOSHIBA multi-function remote-control digital X-ray machine was purchased from Toshiba Medical Systems Co., Ltd.; all the patients were examined by X-ray before and after treatment, and the films were read by 3 attending doctors with 10-year working experience in this hospital. Grading: the lung texture is obviously reduced to be markedly effective, the lung shadow is reduced to be effective, the lung texture is not changed or even increased and aggravated in ineffective result. Total effective rate = markedly effective rate + effective rate.

MSPFT- B pulmonary function instrument was purchased from Shanghai Hanfei Medical Devices Co., Ltd.; main observation indexes were respiratory rate (RR), forced vital capacity (FVC), and first second forced expiratory volume (FEV1).

A 20 m-long straight line was plotted on the flat to record the patient's 6-min walking distance and assess the patient's exercise tolerance.

Levels of IL-6, TNF-α were detected by ELISA; the test kits were purchased from Wuhan Ellette Biotechnology Co., Ltd. (SFDA Approval no. E-EL-H0102c, E-EL-H0109c), and the specific test steps referred to the kit instructions.

SPSS 19.0 (Asia Analytics Formerly SPSS China) was used. Enumeration data were expressed in rates. χ² test was used to compare the rate. Measurement data were expressed in mean ± SD. Independent sample t-test was used for comparison between the two groups. Paired t-test was used for intra-group comparison. The relationship between IL-6, TNF-α and the therapeutic effect was analyzed by ROC curve. P<0.05 was considered a statistically significant difference.